Recent progress in pharmaceutical excipients as P-glycoprotein inhibitors for potential improvement of oral drug bioavailability: A comprehensive overview
Abstract
Pharmaceutical excipients such as P-glycoprotein inhibitors can also increase the solubility and affinity of drugs to the intestinal membrane, enhance paracellular pathways and endocyte uptake, and activate lymph transport pathways, thereby increasing the bioavailability of oral drugs. This review aims to review and assess the performance of pharmaceutical excipients as P-glycoprotein permeability inhibitors in improving oral drug bioavailability in drug formulations by evaluating meta data from P-glycoprotein efflux in permeability and pharmacokinetics studies.
The review results are pharmaceutical excipients that have proven effective as P-glycoprotein inhibitors from the surfactant and polymer groups, namely TPGS and Poloxamer 188, respectively. All nanosystems incorporating pharmaceutical excipients as P-gp inhibitors show potential in enhancing the permeability and bioavailability of oral drugs when compared to conventional formulations. The effectiveness of these systems has been evaluated through in vitro (Caco-2 cells), ex vivo (everted gut sac), in situ (SPIP), and in vivo (AUC) methods.
Download the full article as PDF here: Recent progress in pharmaceutical excipients as P-glycoprotein inhibitors for potential improvement of oral drug bioavailability: A comprehensive overview
or read it here
Table 2. The excipients as P-gp inhibitors
| Type | Group | Material | References |
|---|---|---|---|
| Surfactant | Polysorbates | – Polysorbate 80 | (Constantinides and Wasan 2007; Kou et al. 2018) |
| – Polysorbate 20 | |||
| Sucrose esters | Sucrose monolaurate | ||
| Tocopheryl ester | Tocopheryl polyethylene glycol succinate (TPGS) | ||
| PEG esters | – PEG-35 castor oil (Cremophor® EL) | ||
| – PEG-12-hydroxystearate (Kolliphor® HS 15/Solutol® HS-15) | |||
| – PEG-8 glyceryl caprylate/caprate (Labrasol®) | |||
| – PEG-6 glyceryl caprylate/caprate (Softigen® 767) | |||
| – PEG-32 Glyceryl laureate (Gelucire 44/14) | |||
| – Polyoxyethylene (40) stearate (Myrj 52) | |||
| PEG ethers | Polyoxyethylene (20) stearyl ether (Brij 78) | ||
| Others | – Natrium 1,4-bis (2-etilheksioksi)-1,4 – dioxobutane– 2-sulfonate (AOT) | ||
| – Cetyltrimethylammonium bromide (CTAB) | |||
| Polymer | Natural polymers | Dextrans, Agar, Gellan gum, Gum arabic, Gum traganth, Guar gum, Carrageenan gum, Xanthan gum, Alginates, Chitosan. | (Constantinides and Wasan 2007; Kou et al. 2018) |
| Amphiphilic diblock copolymers | – MethoxyPEG-block-polycaprolactone (MePEG-b-PCL) | ||
| – Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer (Soluplus®) | |||
| Pluronic block copolymers | – Pluronic F127/Poloxamer 407 | ||
| – Pluronic F68/Poloxamer 188 | |||
| Lipid-based excipients | Glycerides | – Monoolein (PeceolTM) | (Constantinides and Wasan 2007; Kou et al. 2018) |
| – Monostearin | |||
| Phospholipids | – 1,2-dioctanoyl-sn-glycero-3-phosphocholine (8:0 PC) | ||
| – 1,2-didecanoyl-sn-glycero-3-phosphocholine (10:0 PC) | |||
| Methylated cyclodextrin | Methyl-β-cyclodextrin |
Darusman F, Rusdiana T, Sopyan I, Rahma H, Hanifa M (2025) Recent progress in pharmaceutical excipients as P-glycoprotein inhibitors for potential improvement of oral drug bioavailability: A comprehensive overview. Pharmacia 72: 1–16. https://doi. org/10.3897/pharmacia.72.e140734
Are you looking for excipients in commercial quantities?
